- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Humacyte Inc (HUMA)
Humacyte Inc stock price live, this page displays NASDAQ HUMA stock exchange data. View the HUMA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Humacyte Inc real time stock price chart below.
What Is the Humacyte Inc Stock Price Today?
The Humacyte Inc stock price today is 0.717.
What Is the Stock Symbol for Humacyte Inc?
The stock ticker symbol for Humacyte Inc is HUMA.
Is HUMA the Same as $HUMA?
$HUMA is a common way to refer to the Humacyte Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Humacyte Inc Trade On?
Humacyte Inc is listed and trades on the NASDAQ stock exchange.
Is Humacyte Inc a Good Stock to Buy?
Determining whether Humacyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Humacyte Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HUMA quote. (ISIN: US44486Q1031)
What Is the Humacyte Inc Stock Price Today?
The Humacyte Inc stock price today is 0.717.
What Is the Stock Symbol for Humacyte Inc?
The stock ticker symbol for Humacyte Inc is HUMA.
Is HUMA the Same as $HUMA?
$HUMA is a common way to refer to the Humacyte Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Humacyte Inc Trade On?
Humacyte Inc is listed and trades on the NASDAQ stock exchange.
Is Humacyte Inc a Good Stock to Buy?
Determining whether Humacyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Humacyte Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HUMA quote. (ISIN: US44486Q1031)
0.717
+0.026(+3.69%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.704
0.735
52 wk Range
0.547
2.930
HUMA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7040.735
52 wk Range
0.5472.930
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HUMA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
5.103
Upside
+611.70%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte Inc SWOT Analysis
Regulatory Hurdles | Approaching PDUFA date for HAV in vascular trauma, success could catalyze pipeline progress and investor interest amid safety considerations |
Market Potential | Analysts project over $1 billion in annual revenues by 2032, with price targets ranging from $6 to $25, suggesting significant upside potential |
Mixed Clinical Results | Phase 3 study reveals superior efficacy in challenging patient groups, but higher thrombosis rates raise safety concerns for widespread adoption |
HAV Breakthrough | Humacyte's human acellular vessels technology shows promise in vascular treatments, potentially revolutionizing multiple medical applications |
Humacyte Inc Earnings Call Summary for Q4/2025
- Humacyte Q4 2025 revenue of $500K missed analyst forecasts of $1.35M by 63%, while EPS of -$0.13 met expectations; stock fell 5.47% in premarket.
- First commercial year generated $2M in revenue from 61 Symvess units following December 2024 FDA approval, up from zero revenue in 2024.
- Q4 net loss widened to $24.8M from $20.9M year-over-year, with COGS of $9.1M pressuring margins amid high manufacturing overheads.
- Company projects 2026 revenue reaching $10.18M by year-end, targeting expansion in Saudi Arabia and Israel to boost market penetration.
- CEO Niklason acknowledged revenue target challenges while emphasizing commitment to scaling operations and enhancing sales force effectiveness.
Last Updated: 03/27/2026, 09:04 AM
Read Full TranscriptCompare HUMA to Peers and Sector
Metrics to compare | HUMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHUMAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.5x | −0.9x | −0.5x | |
PEG Ratio | −0.06 | −0.15 | 0.00 | |
Price / Book | −34.7x | 1.6x | 2.6x | |
Price / LTM Sales | 104.9x | 31.5x | 3.2x | |
Upside (Analyst Target) | 309.8% | 793.3% | 47.6% | |
Fair Value Upside | Unlock | 17.6% | 6.1% | Unlock |
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.103
(+611.70% Upside)
Earnings
Latest Release
Mar 27, 2026
EPS / Forecast
-0.13 / -0.13
Revenue / Forecast
500K / 1.35M
People Also Watch
FAQ
What Is the Humacyte (HUMA) Stock Price Today?
The Humacyte stock price today is 0.717 USD.
What Stock Exchange Does Humacyte Trade On?
Humacyte is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Humacyte?
The stock symbol for Humacyte is "HUMA."
What Is the Humacyte Market Cap?
As of today, Humacyte market cap is 159.850M USD.
What Is Humacyte's Earnings Per Share (TTM)?
The Humacyte EPS (TTM) is -0.258.
When Is the Next Humacyte Earnings Date?
Humacyte will release its next earnings report on May 08, 2026.
From a Technical Analysis Perspective, Is HUMA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Humacyte Stock Split?
Humacyte has split 0 times.
How Many Employees Does Humacyte Have?
Humacyte has 184 employees.
What is the current trading status of Humacyte (HUMA)?
As of Apr 15, 2026, Humacyte (HUMA) is trading at a price of 0.717 USD, with a previous close of 0.691 USD. The stock has fluctuated within a day range of 0.704 USD to 0.735 USD, while its 52-week range spans from 0.547 USD to 2.930 USD.
What Is Humacyte (HUMA) Price Target According to Analysts?
The average 12-month price target for Humacyte is 5.103 USD, with a high estimate of 25 USD and a low estimate of 1 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +611.70% Upside potential.
What Is the HUMA Premarket Price?
HUMA's last pre-market stock price is 0.718 USD. The pre-market share volume is 131,830.000, and the stock has decreased by 0.027, or 3.850%.
What Is the HUMA After Hours Price?
HUMA's last after hours stock price is 0.716 USD, the stock has decreased by 0.025, or 3.620%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.